METHODS OF EXTRACORPOREAL HEMOCORRECTION IN COMPLEX TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AFTER KIDNEY TRANSPLANTATION
- Authors: Vatazin A.V.1, Astakhov P.V.1, Zulkarnaev A.B.1, Krstic M.1, Kantaria R.O.1, Fedulkina V.A.1
-
Affiliations:
- M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)
- Issue: No 28 (2013)
- Pages: 72-78
- Section: SCIENTIFIC REVIEWS, LECTURES
- URL: https://almclinmed.ru/jour/article/view/14
- DOI: https://doi.org/10.18786/2072-0505-2013-28-72-78
- ID: 14
Cite item
Full Text
Abstract
Scientific publications devoted to the contemporary prospective selected and combined extracorporeal modalities to treat complications after renal allotransplantation were analyzed involving pyoseptic processes and viral hepatites.
About the authors
A. V. Vatazin
M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)
Author for correspondence.
Email: fake@neicon.ru
Россия
P. V. Astakhov
M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)
Email: fake@neicon.ru
Россия
A. B. Zulkarnaev
M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)
Email: fake@neicon.ru
Россия
M. Krstic
M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)
Email: fake@neicon.ru
Россия
R. O. Kantaria
M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)
Email: fake@neicon.ru
Россия
V. A. Fedulkina
M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)
Email: fake@neicon.ru
Россия
References
- Введенский Д.В., Кирковский В.В., Голубович В.П. и др. Клиническая эффективность биоспецифического гемо-сорбента «Липосорб» // Вестн. РАМН. 2009. №10. С.40-43.
- Хорошилов С.Е., Карпун Н.А., Половников С.Г. и др. Селективная гемосорбция эндотоксина в лечении абдоминального сепсиса // Общая реаниматология. 2009. №6. С.83-87.
- Antonelli M., Fumagalli R., Cruz D.N. et al. PMX endotoxin removal in the clinical practice: results from the EUPHAS trial // Contrib. Nephrol. 2010. V.167. P.83-90.
- Bellomo R., Tetta C., Ronco C. Coupled plasma filtration adsorption // Intensive Care Med. 2003. V.29, No.8. P.1222-1228.
- Berlot G., Bianco N., Tomasini A. et al. Changes in microvascular blood flow during coupled plasma filtration and adsorption // Anaesth. Intens. Care. 2011. V.39, No.4. P.687-689.
- Braks R.E., Ganne-Carrie N., Fontaine H. et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin // World J. Gastroenterol. 2007. V.13, No.42. P.5648-5653.
- Cardoso A.C., Moucari R., Figueiredo-Mendes C. et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis // J. Hepatol. 2010. V.52, No.5. P.652-657.
- Cavaillon J.M. Polymyxin B for endotoxin removal in sepsis // Lancet Infect. Dis. 2011. V.11, No.6. P.426-427.
- Cruz D.N., Perazella M.A., Bellomo R. et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review // Crit Care. 2007. V.11, No.2. Р.47.
- Davies B., Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock // Lancet Infect. Dis. 2011. V.11, No.1. P.65-71.
- Formica M., Inguaggiato P., Bainotti S., Wratten M.L. Coupled plasma filtration adsorption // Contrib. Nephrol. 2007. No.156. P.405-410.
- Fujiwara K., Kaneko S., Kakumu S. et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load // Hepatol. Res. 2007. V.37, No.9. P.701-710.
- Hanafusa N., Kondo Y., Suzuki M. et al. Double filtration plasmapheresis can decrease factor XIII Activity // Ther. Apher. Dial. 2007. V.11, No.3. P.165-170.
- Honoré P.M., Joannes-Boyau O., Collin V. et al. Continuous hemofiltration in 2009: what is new for clinicians regarding pathophysiology, preferred technique and recommended dose? // Blood Purif. 2009. V.28, No.2. P.135-143.
- Ishikawa T., Higuchi K., Kubota T. et al. Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy // Ther. Apher. Dial. 2011. V.15, No.4. P.400-405.
- Kaneko S., Sata M., Ide T. et al. Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C // Hepatol. Res. 2010. V.40, No.11. P.1072-1081.
- Kim S.R., Imoto S., Kudo M. et al. Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics // Intervirology. 2010. V.53, No.1. P.44-48.
- Kondo Y., Ueno Y., Wakui Y. et al. Rapid reduction of hepatitis C virus-Core protein in the peripheral blood improve the immunological response in chronic hepatitis C patients // Hepatol. Res. 2011. V.41, No.12. P.1153-1168.
- Kushi H., Miki T. Haeoperfusion with an immobilized Plymyxin B column reduces the blood level of neutrophil elastase // Blood Purifcat. 2006. V.24. P.212-217.
- Kushi H., Miki T., Sakagami Y. et al. Hemoperfusion with an immobilized polymyxin B fiber column decreases macrophage and monocyte activity // Ther. Apher. Dial. 2009. V.13, No.6. P.515-519.
- Kushi H., Miki T., Sakagami Y. et al. Hemoperfusion with a polymyxin B fiber column decreases clotting activity // Ther. Apher. Dial. 2009. V.13, No.6. P.528-533.
- Mao H.J., Yu S., Yu X.B. et al. Effects of coupled plasma filtration adsorption on immune function of patients with multiple organ dysfunction syndrome // Int. J. Artif. Organs. 2009. V.32, No.1. P.31-38.
- Naka T., Shinozaki M. The effect of continuous veno-venous haemofiltration or direct hemoperfusion with Polymyxin B-immobilized fiber on neutrophil respiratory oxidative burst in patients with sepsis and septic shock // Ther. Apher. Dial. 2006. V.10, No.1. P.7-11.
- Nakamura M., Oda S., Sadahiro T. et al. Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator // Contrib. Nephrol. 2010. No.166. P.73-82.
- Namba T., Shiba R., Yamamoto T. et al. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy // Clin. Exp. Nephrol. 2010. V.14, No.4. P.372-376.
- Novelli G., Ferretti G., Poli L. et al. Clinical results of treatment of postsurgical endotoxin-mediated sepsis with polymyxin-B direct hemoperfusion // Transplant. Proc. 2010. V.42, No.4. P.1021-1024.
- Ohara T., Oteki T., Suzuki T. et al. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination // Hepatogastroenterology. 2011. V.58, No.105. P.133-136.
- Payen D., Mateo J., Cavaillon J.M. et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial // Crit. Care Med. 2009. V.37, No.3. P.803-810.
- Peng Z., Pai P., Hong-Bao L. et al. The impacts of continuous veno-venous hemofiltration on plasma cytokines and monocyte human leukocyte antigen-DR expression in septic patients // Cytokine. 2010. V.50, No.2. P.186-191.
- Peng Z., Singbartl K., Simon P. et al. Blood purification in sepsis: a new paradigm // Contrib. Nephrol. 2010. No.165. P.322-328.
- Rachoin J.S., Foster D., Dellinger R.P. Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES // Contrib. Nephrol. 2010. No.167. P.111-118.
- Ramasubban S., Majumdar A., Das P.S. Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock // Indian J. Crit. Care Med. 2008. V.12, No.4. P.153-157.
- Ronco C., Piccinni P., Kellum J. Rationale of extracorporeal removal of endotoxin in sepsis: theory, timing and technique // Contrib. Nephrol. 2010. No.167. P.25-34.
- Sakamoto Y., Mashiko K., Obata T. et al. Effectiveness of continuous hemodiafiltration using a polymethylmethacry-late membrane hemofilter after polymyxin B-immobilized fiber column therapy of septic shock // ASAIO J. 2008. V.54, No.1. P.129-132.
- Sato K., Maekawa H., Sakurada M. et al. Direct hemoper-fusion with polymyxin B immobilized fiber for abdominal sepsis in Europe // Surg. Today. 2011. V.41, No.6. P.754-760.
- Shimizu T., Hanasawa K., Sato K. et al. Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation // Langenbecks Arch. Surg. 2009. V.394, No.2. P.303-311.
- Stengl M., Sykora R., Chvojka J. et al. Differential effects of hemofiltration and of coupled plasma filtration adsorption on cardiac repolarization in pigs with hyperdynamic septic shock // Shock. 2010. V.33, No.1. P.101-105.
- Sykora R., Chvojka J., Krouzecky A. et al. Coupled plasma filtration adsorption in experimental peritonitis-induced septic shock // Shock. 2009. V.31, No.5. P.473-480.
- Takada Y., Ito T., Ueda Y. et al. Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation // Liver Transpl. 2008. V.14, No.7. P.1044-1047.
- Taniguchi M., Furukawa H., Shimamura T. et al. Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C // Transplantation. 2006. V.81, No.12. P.1747-1749.
- Taniguchi T. Cytokine adsorbing columns // Contrib. Nephrol. 2010. No.166. P.134-141.
- Wong J.B., Davis G.L., McHutchison J.G. et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C // Am. J. Gastroenterol. 2003. V.98, No.11. P.2354-2362.
- Yamashita T., Arai K., Sakai A. et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study // Hepatol. Res. 2006. V.36, No.3. P.167-175.